Pramipexole: a nonergot dopamine agonist as drug therapy in Parkinson’s disease

References

• Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. NeuroL Clin. 14(2), 317–335 (1996).
   Google Scholar
• Cotzias GC, Van Woert MH, Schiffer LM. Aromatic aminoacids and modification of parkinsonism. N Engl. j Med. 276(7), 374–379 (1967).
   Google Scholar
• Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1,345–349 (1977).
   PubMed Web of Science ®Google Scholar
• Obeso JA, Grandas F, Vaamonde J et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease.Neurology39\(Suppl. 2), 11–19 (1989).
   Google Scholar
• Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23(10), S2—S7 (2000).
   Web of Science ®Google Scholar
• •This supplementary volume of Trends in Neurosciences offers a comprehensive review of the basal ganglia, PD, its therapies and therapeutic complications.
   Google Scholar
• Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur. j Pharmacol 14,215(2–3), 161–170 (1992).
   Google Scholar
• Wright CE, Sisson TL, Ichhpurani AK et al. Steady-state pharmakokinetic properties of pramipexole in healthy volunteers. J. Clin. PharmacoL37, 520–525 (1997).
   PubMed Web of Science ®Google Scholar
• Hubble JP, Koller WC, Cutler NR et al. Pramipexole in patients with early Parkinson's disease. Clin. NeuropharmacoL 18(4), 338–347 (1995).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study. JAMA 278(2), 125–130 (1997).
   PubMed Web of Science ®Google Scholar
• Shannon KM, Bennett JP, Jr., Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology49 (3), 724–728 (1997).
   Google Scholar
• Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson's disease: A randomized controlled trial. JAMA 284(15), 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• ••This clinical trial report provides detailedinformation regarding the effects and treatment complications of the dopamine agonist pramipexole compared to levodopa in mild-to-moderate PD.
   Google Scholar
• Seibyl JP, Marek KL, Quinlan D et al. Decreased SPECT [I-123] 13-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease. Ann. NeuroL 38,589–598 (1995).
   Google Scholar
• Zou L, Jankovic J, Rowe DB et al. Neuroprotection by pramipexole against dopamine- and levodopa-induced cy. totoxicity. Life Sci. 64 (15), 1275–1285 (1999).
   PubMed Web of Science ®Google Scholar
• Zou L, Xu J, Jankovic J et al. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-12,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci. Lett. 10,281 (2–3), 167–170 (2000).
   Google Scholar
• Rascol O, Brooks DJ, Korczyn AD eta]. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N EngL J. Med. 342,1484–1491 (2000).
   Google Scholar
• Mohlo ES, Factor SA, Weiner WJ eta]. The use of pramipexole, a novel dopamine agonist (DA), in advanced Parkinson's disease. J. NeuraL Transm. 45(Suppl.), 225–230 (1995).
   Google Scholar
• Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology49(1), 162–168 (1997).
   PubMed Web of Science ®Google Scholar
• Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 49(4), 1060–1065 (1997).
   PubMed Web of Science ®Google Scholar
• Pinter MM, Pogarell O, Oertel WH. Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double-blind, placebo-controlled, randomized, multicentre study. J. NeuroL Neurosurg. PTchiatry66(4), 436–441 (1999).
   Google Scholar
• Pinter MM, Rutgers AW, Hebenstreit E. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease. J. Neural. Transm. 107(11), 1307–1323 (2000).
   Google Scholar
• Frucht S, Rogers JD, Greene PE eta]. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology10 52(9), 1908-1910 (1999).
   Google Scholar
• Pal PK, Caine S, Samii A Fleming JAE. A review of normal sleep and its disturbances in Parkinson's disease. Parkinson Re/at. Disord. 5,1–17 (1999).
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 355,1333–1334 (2000).
   PubMed Web of Science ®Google Scholar
• Corrigan MH, Denahan A0, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine and placebo in patients with major depression. Depress. Arvdetyll (2), 58–65 (2000).
   Google Scholar
• Guttman M, Pramipexole PSP Study Group. Double-blind, placebo-controlled trial of pramipexole in Progressive Supranuclear Palsy (PSP). Neurology 56(3), A458 (2001).
   Google Scholar
• Montplaisir J, Boucher S, Pokier G, Lavigne G, Lapierre O, Lespérance P. Clinical polysonmographic and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov. Disord 12,61–65 (1996).
   Google Scholar
• Ling ZD, Robie HC, Tong CW et al. Both the anti-oxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J. Pharmacol. Exp. Ther 289(1), 202–210 (1999).
   Google Scholar
• Kitamura Y, Kosaka T, Kakimura JI et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol 54(6), 1046–1054 (1998).
   Google Scholar
• Hubble JR Preclinical studies of pramipexole: clinical relevance. Review. Eur. Neurol. 7 (Suppl. 1), 15–20 (2000).
   Google Scholar